Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323803 · ClinicalTrials.gov registry record
Eosinophilic Esophagitis Databank
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 709
- Enrollment target
NCT01323803: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01323803 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 709 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01323803 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 709 participants
- Enrollment target
Study Summary
This study will establish a registry for participants with eosinophilic esophagitis (EoE) and create a research resource that will provide further insights into EoE.
Primary Outcome
A Genome-Wide Association Study (GWAS) analysis of single-nucleotide polymorphisms (SNPs) from \>1.5 million genetic markers will be conducted.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 709 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-02 |
What the finished NCT01323803 record still lists
NCT01323803 is an observational study that tracks outcomes without assigning an intervention. The registered 709 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01323803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01323803 about?
NCT01323803 is a clinical study titled "Eosinophilic Esophagitis Databank". This study will establish a registry for participants with eosinophilic esophagitis (EoE) and create a research resource that will provide further insights into EoE.
What is the current status of trial NCT01323803?
This trial is currently completed. The enrollment target is 709 participants. The study started on 2011-04. Estimated completion is 2016-02.
Who is sponsoring clinical trial NCT01323803?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia